首页> 中文期刊> 《中国神经再生研究:英文版》 >Designing nanocarriers to overcome the limitations in conventional drug administration for Parkinson’s disease

Designing nanocarriers to overcome the limitations in conventional drug administration for Parkinson’s disease

         

摘要

Neurodegenerative diseases(NDs)have become one of the leading causes of death and disability worldwide,and cause enormous pain and suffering for both patients and their families.Some of the most common NDs include Alzheimer’s disease,Parkinson’s disease(PD)and Huntington’s disease,among others(Feng,2020).PD is a widespread neurodegenerative disease that affects more than 10 million people worldwide(No author listed,2021).The direct cause of the disease is unknown,but it is characterized by the selective degeneration of dopaminergic neurons in the midbrain in the substantia nigra.This leads to the depletion of dopamine(3,4-dihydroxyphenethylamine,DA)in the striatum of patients,in addition to the existence of abnormalα-synuclein in nerve cells and the development of toxic protein aggregates in neurons called Lewy bodies,which causes muscle stiffness,slowness of movements and tremors.It is believed that a combination of genetic and environmental factors may be the cause of PD,but the exact reason for the disease is not yet fully understood.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号